Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy

Julie Marie Vose, J. E. Anderson, Philip Jay Bierman, F. R. Appelbaum, J. R. Anderson, L. Garrison, M. E. Lebsack, James Olen Armitage

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) was conducted to evaluate the safety and clinical potential of this agent. Patients and Methods: Fifty patients with Hodgkin's disease or non-Hodgkin's lymphoma (NHL) undergoing HDT and ABMT received PIXY321 post-ABMT in doses that ranged from 50 to 1,000 μg/m2/d either as intravenous (IV) or subcutaneous (SC) dosing until engraftment was reached. Results: If all doses are considered together, the median time to reach an absolute neutrophil count (ANC) ≥ 500/μL was 18 days and the median time to platelet transfusion independence was 21 days. At the estimated optimum dose of 750 μg/m2/d by SC injection once daily, the median time to reach an ANC ≥ 500/μL was 15 days and the median time to platelet transfusion independence was 16 days. Historical control patients who received granulocyte-macrophage colony-stimulating factor (GM-CSF) had a median time to an ANC ≥ 500/μL of 19 days and a median time to platelet independence of 26 days. Conclusion: The administration of PIXY321 post-ABMT was generally well tolerated and resulted in prompt engraftment in the majority of patients who underwent HDT and ABMT for lymphoid malignancies. The optimum dose and route of administration of PIXY321 suggested by this trial was 750 μg/m2/d by once-daily SC injection. Compared with historical control patients who received 2-hour IV GM-CSF, patients who received PIXY321 at 750 μg/m2/d by SC injection once daily had an improvement in the median days to neutrophil and platelet engraftment by 4 and 10 days, respectively.

Original languageEnglish (US)
Pages (from-to)520-526
Number of pages7
JournalJournal of Clinical Oncology
Volume14
Issue number2
DOIs
StatePublished - Jan 1 1996

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Neutrophils
Subcutaneous Injections
Neoplasms
Platelet Transfusion
Granulocyte-Macrophage Colony-Stimulating Factor
Blood Platelets
Hodgkin Disease
Non-Hodgkin's Lymphoma
Therapeutics
Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. / Vose, Julie Marie; Anderson, J. E.; Bierman, Philip Jay; Appelbaum, F. R.; Anderson, J. R.; Garrison, L.; Lebsack, M. E.; Armitage, James Olen.

In: Journal of Clinical Oncology, Vol. 14, No. 2, 01.01.1996, p. 520-526.

Research output: Contribution to journalArticle

@article{7b2d056f8cae423f9369ecc62a05392f,
title = "Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy",
abstract = "Purpose: A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) was conducted to evaluate the safety and clinical potential of this agent. Patients and Methods: Fifty patients with Hodgkin's disease or non-Hodgkin's lymphoma (NHL) undergoing HDT and ABMT received PIXY321 post-ABMT in doses that ranged from 50 to 1,000 μg/m2/d either as intravenous (IV) or subcutaneous (SC) dosing until engraftment was reached. Results: If all doses are considered together, the median time to reach an absolute neutrophil count (ANC) ≥ 500/μL was 18 days and the median time to platelet transfusion independence was 21 days. At the estimated optimum dose of 750 μg/m2/d by SC injection once daily, the median time to reach an ANC ≥ 500/μL was 15 days and the median time to platelet transfusion independence was 16 days. Historical control patients who received granulocyte-macrophage colony-stimulating factor (GM-CSF) had a median time to an ANC ≥ 500/μL of 19 days and a median time to platelet independence of 26 days. Conclusion: The administration of PIXY321 post-ABMT was generally well tolerated and resulted in prompt engraftment in the majority of patients who underwent HDT and ABMT for lymphoid malignancies. The optimum dose and route of administration of PIXY321 suggested by this trial was 750 μg/m2/d by once-daily SC injection. Compared with historical control patients who received 2-hour IV GM-CSF, patients who received PIXY321 at 750 μg/m2/d by SC injection once daily had an improvement in the median days to neutrophil and platelet engraftment by 4 and 10 days, respectively.",
author = "Vose, {Julie Marie} and Anderson, {J. E.} and Bierman, {Philip Jay} and Appelbaum, {F. R.} and Anderson, {J. R.} and L. Garrison and Lebsack, {M. E.} and Armitage, {James Olen}",
year = "1996",
month = "1",
day = "1",
doi = "10.1200/JCO.1996.14.2.520",
language = "English (US)",
volume = "14",
pages = "520--526",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy

AU - Vose, Julie Marie

AU - Anderson, J. E.

AU - Bierman, Philip Jay

AU - Appelbaum, F. R.

AU - Anderson, J. R.

AU - Garrison, L.

AU - Lebsack, M. E.

AU - Armitage, James Olen

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose: A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) was conducted to evaluate the safety and clinical potential of this agent. Patients and Methods: Fifty patients with Hodgkin's disease or non-Hodgkin's lymphoma (NHL) undergoing HDT and ABMT received PIXY321 post-ABMT in doses that ranged from 50 to 1,000 μg/m2/d either as intravenous (IV) or subcutaneous (SC) dosing until engraftment was reached. Results: If all doses are considered together, the median time to reach an absolute neutrophil count (ANC) ≥ 500/μL was 18 days and the median time to platelet transfusion independence was 21 days. At the estimated optimum dose of 750 μg/m2/d by SC injection once daily, the median time to reach an ANC ≥ 500/μL was 15 days and the median time to platelet transfusion independence was 16 days. Historical control patients who received granulocyte-macrophage colony-stimulating factor (GM-CSF) had a median time to an ANC ≥ 500/μL of 19 days and a median time to platelet independence of 26 days. Conclusion: The administration of PIXY321 post-ABMT was generally well tolerated and resulted in prompt engraftment in the majority of patients who underwent HDT and ABMT for lymphoid malignancies. The optimum dose and route of administration of PIXY321 suggested by this trial was 750 μg/m2/d by once-daily SC injection. Compared with historical control patients who received 2-hour IV GM-CSF, patients who received PIXY321 at 750 μg/m2/d by SC injection once daily had an improvement in the median days to neutrophil and platelet engraftment by 4 and 10 days, respectively.

AB - Purpose: A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) was conducted to evaluate the safety and clinical potential of this agent. Patients and Methods: Fifty patients with Hodgkin's disease or non-Hodgkin's lymphoma (NHL) undergoing HDT and ABMT received PIXY321 post-ABMT in doses that ranged from 50 to 1,000 μg/m2/d either as intravenous (IV) or subcutaneous (SC) dosing until engraftment was reached. Results: If all doses are considered together, the median time to reach an absolute neutrophil count (ANC) ≥ 500/μL was 18 days and the median time to platelet transfusion independence was 21 days. At the estimated optimum dose of 750 μg/m2/d by SC injection once daily, the median time to reach an ANC ≥ 500/μL was 15 days and the median time to platelet transfusion independence was 16 days. Historical control patients who received granulocyte-macrophage colony-stimulating factor (GM-CSF) had a median time to an ANC ≥ 500/μL of 19 days and a median time to platelet independence of 26 days. Conclusion: The administration of PIXY321 post-ABMT was generally well tolerated and resulted in prompt engraftment in the majority of patients who underwent HDT and ABMT for lymphoid malignancies. The optimum dose and route of administration of PIXY321 suggested by this trial was 750 μg/m2/d by once-daily SC injection. Compared with historical control patients who received 2-hour IV GM-CSF, patients who received PIXY321 at 750 μg/m2/d by SC injection once daily had an improvement in the median days to neutrophil and platelet engraftment by 4 and 10 days, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0030061368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030061368&partnerID=8YFLogxK

U2 - 10.1200/JCO.1996.14.2.520

DO - 10.1200/JCO.1996.14.2.520

M3 - Article

VL - 14

SP - 520

EP - 526

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -